NasdaqGS:IART

Stock Analysis Report

Integra LifeSciences Holdings

Executive Summary

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.

Snowflake

Fundamentals

Acceptable track record with moderate growth potential.


Similar Companies

Share Price & News

How has Integra LifeSciences Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.4%

NasdaqGS:IART

2.9%

US Medical Equipment

2.9%

US Market


1 Year Return

4.3%

NasdaqGS:IART

14.0%

US Medical Equipment

0.2%

US Market

IART underperformed the Medical Equipment industry which returned 14.1% over the past year.

IART outperformed the Market in United States of America which returned -0.7% over the past year.


Share holder returns

IARTIndustryMarket
7 Day1.4%2.9%2.9%
30 Day13.0%0.8%-2.3%
90 Day26.4%11.3%3.1%
1 Year4.3%4.3%14.9%14.0%2.4%0.2%
3 Year45.8%45.8%71.4%66.1%41.7%32.4%
5 Year173.3%147.0%134.0%107.1%55.1%37.9%

Price Volatility Vs. Market

How volatile is Integra LifeSciences Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Integra LifeSciences Holdings undervalued based on future cash flows and its price relative to the stock market?

12%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Integra LifeSciences Holdings's share price is below the future cash flow value, but not at a moderate discount (< 20%).

Integra LifeSciences Holdings's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Integra LifeSciences Holdings is overvalued based on earnings compared to the US Medical Equipment industry average.

Integra LifeSciences Holdings is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Integra LifeSciences Holdings is poor value based on expected growth next year.


Price Based on Value of Assets

Integra LifeSciences Holdings is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Integra LifeSciences Holdings expected to perform in the next 1 to 3 years based on estimates from 15 analysts?

28.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Integra LifeSciences Holdings's revenue is expected to grow by 5.3% yearly, however this is not considered high growth (20% yearly).

Integra LifeSciences Holdings's earnings are expected to grow significantly at over 20% yearly.

Integra LifeSciences Holdings's revenue growth is positive but not above the United States of America market average.

Integra LifeSciences Holdings's earnings growth is expected to exceed the United States of America market average.

Integra LifeSciences Holdings's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Integra LifeSciences Holdings is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Integra LifeSciences Holdings performed over the past 5 years?

29.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Integra LifeSciences Holdings has delivered over 20% year on year earnings growth in the past 5 years.

Integra LifeSciences Holdings's 1-year earnings growth exceeds its 5-year average (44.4% vs 29.6%)

Integra LifeSciences Holdings's earnings growth has exceeded the US Medical Equipment industry average in the past year (44.4% vs 28.9%).


Return on Equity

Integra LifeSciences Holdings has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Integra LifeSciences Holdings used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Integra LifeSciences Holdings's use of capital has not improved over the past 3 years (Return on Capital Employed).


Next Steps

Financial Health

How is Integra LifeSciences Holdings's financial position?


Financial Position Analysis

Integra LifeSciences Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Integra LifeSciences Holdings's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Integra LifeSciences Holdings's level of debt (98.2%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (91.8% vs 98.2% today).

Debt is not well covered by operating cash flow (14.3%, less than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 5.3x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is not covered by short term assets, assets are 0.6x debt.


Next Steps

Dividend

What is Integra LifeSciences Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Integra LifeSciences Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Integra LifeSciences Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Integra LifeSciences Holdings has not reported any payouts.

Unable to verify if Integra LifeSciences Holdings's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Integra LifeSciences Holdings has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Integra LifeSciences Holdings's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Integra LifeSciences Holdings's salary, the management and board of directors tenure and is there insider trading?

2.7yrs

Average management tenure


CEO

Pete Arduini (54yo)

7.6yrs

Tenure

US$7,647,812

Compensation

Mr. Peter J. Arduini, also known as Pete, has been Chief Executive Officer and President at Derma Sciences, Inc. since February 2017. Mr. Arduini has been the Chief Executive Officer of Integra LifeScience ...


CEO Compensation Analysis

Pete's remuneration is about average for companies of similar size in United States of America.

Pete's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.7yrs

Average Tenure

54yo

Average Age

The tenure for the Integra LifeSciences Holdings management team is about average.


Board Age and Tenure

7.0yrs

Average Tenure

61.5yo

Average Age

The tenure for the Integra LifeSciences Holdings board of directors is about average.


Insider Trading

Integra LifeSciences Holdings individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$252,24620 Aug 19
Raymond Murphy
EntityIndividual
Role
Member of the Board of Directors
Director
Shares4,136
Max PriceUS$60.99
SellUS$74,69331 Jul 19
Jeffrey Mosebrook
EntityIndividual
Role
Chief Accounting Officer
VP, Principal Accounting Officer & Corporate Controller
Shares1,179
Max PriceUS$63.35
SellUS$149,94030 Jul 19
Lisa Evoli
EntityIndividual
Shares2,380
Max PriceUS$63.00
SellUS$72,16718 Mar 19
Lisa Evoli
EntityIndividual
Shares1,291
Max PriceUS$55.90
BuyUS$108,39918 Mar 19
Rhonda Ballintyn
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,933
Max PriceUS$56.08
BuyUS$199,68306 Nov 18
Barbara Hill
EntityIndividual
Role
Lead Director
Presiding Director
Shares3,705
Max PriceUS$53.90
SellUS$2,949,51918 Oct 18
Provco Leasing Corporation
EntityCompany
Shares46,676
Max PriceUS$63.22

Ownership Breakdown


Management Team

  • Richard Caruso (76yo)

    Founder and Chairman Emeritus

    • Tenure: 2.3yrs
    • Compensation: US$37.50k
  • Dan Reuvers (56yo)

    Corporate VP & President of Specialty Surgical Solutions

    • Tenure: 2.7yrs
    • Compensation: US$1.82m
  • Pete Arduini (54yo)

    President

    • Tenure: 7.6yrs
    • Compensation: US$7.65m
  • Eric Schwartz (50yo)

    Corporate VP

    • Tenure: 0.8yrs
    • Compensation: US$1.14m
  • Glenn Coleman (51yo)

    COO & Corporate VP of International

    • Tenure: 0.2yrs
    • Compensation: US$2.29m
  • Ken Burhop (65yo)

    Corporate VP & Chief Scientific Officer

    • Tenure: 5.5yrs
  • Bob Davis (60yo)

    Corporate VP and President of Orthopedics & Tissue Technologies

    • Tenure: 6.7yrs
    • Compensation: US$1.37m
  • William Compton

    Chief Information Officer & Senior VP

    • Tenure: 0.0yrs
  • Carrie Anderson (50yo)

    Corporate VP

    • Tenure: 0.2yrs
  • Jeffrey Mosebrook (43yo)

    VP, Principal Accounting Officer & Corporate Controller

    • Tenure: 1.8yrs

Board Members

  • Ray Murphy (71yo)

    Director

    • Tenure: 10.3yrs
    • Compensation: US$282.58k
  • Richard Caruso (76yo)

    Founder and Chairman Emeritus

    • Tenure: 2.3yrs
    • Compensation: US$37.50k
  • Donald Morel (61yo)

    Director

    • Tenure: 6.0yrs
    • Compensation: US$270.03k
  • Chris Schade (58yo)

    Director

    • Tenure: 13.6yrs
    • Compensation: US$280.03k
  • Stuart Essig (57yo)

    Chairman

    • Tenure: 7.6yrs
    • Compensation: US$370.07k
  • Barbara Hill (67yo)

    Presiding Director

    • Tenure: 0.9yrs
    • Compensation: US$275.14k
  • Keith N. Bradley (74yo)

    Director

    • Tenure: 27.6yrs
    • Compensation: US$275.08k
  • Rhonda Ballintyn (62yo)

    Director

    • Tenure: 0.6yrs
  • Pete Arduini (54yo)

    President

    • Tenure: 7.6yrs
    • Compensation: US$7.65m
  • Lloyd Howell (52yo)

    Director

    • Tenure: 6.4yrs
    • Compensation: US$265.08k

Company Information

Integra LifeSciences Holdings Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Integra LifeSciences Holdings Corporation
  • Ticker: IART
  • Exchange: NasdaqGS
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$5.283b
  • Shares outstanding: 85.53m
  • Website: https://www.integralife.com

Number of Employees


Location

  • Integra LifeSciences Holdings Corporation
  • 311 Enterprise Drive
  • Plainsboro
  • New Jersey
  • 8536
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IARTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 1995
IL3DB (Deutsche Boerse AG)YesCommon StockDEEURAug 1995

Biography

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 23:39
End of Day Share Price2019/08/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.